Literature DB >> 26173894

Accurate analysis and visualization of cardiac (11)C-PIB uptake in amyloidosis with semiautomatic software.

Tanja Kero1, Lars Lindsjö2, Jens Sörensen2, Mark Lubberink2.   

Abstract

BACKGROUND: (11)C-PIB PET is a promising non-invasive diagnostic tool for cardiac amyloidosis. Semiautomatic analysis of PET data is now available but it is not known how accurate these methods are for amyloid imaging. The aim of this study was to evaluate the feasibility of one semiautomatic software tool for analysis and visualization of (11)C-PIB left ventricular retention index (RI) in cardiac amyloidosis. METHODS AND
RESULTS: Patients with systemic amyloidosis and cardiac involvement (n = 10) and healthy controls (n = 5) were investigated with dynamic (11)C-PIB PET. Two observers analyzed the PET studies with semiautomatic software to calculate the left ventricular RI of (11)C-PIB and to create parametric images. The mean RI at 15-25 min from the semiautomatic analysis was compared with RI based on manual analysis and showed comparable values (0.056 vs 0.054 min(-1) for amyloidosis patients and 0.024 vs 0.025 min(-1) in healthy controls; P = .78) and the correlation was excellent (r = 0.98). Inter-reader reproducibility also was excellent (intraclass correlation coefficient, ICC > 0.98). Parametric polarmaps and histograms made visual separation of amyloidosis patients and healthy controls fast and simple.
CONCLUSION: Accurate semiautomatic analysis of cardiac (11)C-PIB RI in amyloidosis patients is feasible. Parametric polarmaps and histograms make visual interpretation fast and simple.

Entities:  

Keywords:  Amyloid; C-11 PIB; PET imaging; cardiac amyloidosis

Mesh:

Substances:

Year:  2015        PMID: 26173894     DOI: 10.1007/s12350-015-0149-9

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  24 in total

Review 1.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.

Authors:  Manuel D Cerqueira; Neil J Weissman; Vasken Dilsizian; Alice K Jacobs; Sanjiv Kaul; Waren K Laskey; Dudley J Pennell; John A Rumberger; Thomas Ryan; Mario S Verani
Journal:  Int J Cardiovasc Imaging       Date:  2002-02       Impact factor: 2.357

2.  Clarification of a fractional uptake concept.

Authors:  J A Thie
Journal:  J Nucl Med       Date:  1995-04       Impact factor: 10.057

3.  Quantification of extracellular matrix expansion by CMR in infiltrative heart disease.

Authors:  François-Pierre Mongeon; Michael Jerosch-Herold; Otávio Rizzi Coelho-Filho; Ron Blankstein; Rodney H Falk; Raymond Y Kwong
Journal:  JACC Cardiovasc Imaging       Date:  2012-09

4.  Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m labelled aprotinin.

Authors:  C Aprile; G Marinone; R Saponaro; C Bonino; G Merlini
Journal:  Eur J Nucl Med       Date:  1995-12

5.  Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis.

Authors:  Imran S Syed; James F Glockner; Dali Feng; Philip A Araoz; Matthew W Martinez; William D Edwards; Morie A Gertz; Angela Dispenzieri; Jae K Oh; Diego Bellavia; A Jamil Tajik; Martha Grogan
Journal:  JACC Cardiovasc Imaging       Date:  2010-02

Review 6.  Evaluation and management of the cardiac amyloidosis.

Authors:  Joseph B Selvanayagam; Philip N Hawkins; Biju Paul; Saul G Myerson; Stefan Neubauer
Journal:  J Am Coll Cardiol       Date:  2007-11-13       Impact factor: 24.094

Review 7.  Nuclear imaging modalities for cardiac amyloidosis.

Authors:  Sabahat Bokhari; Reehan Shahzad; Adam Castaño; Mathew S Maurer
Journal:  J Nucl Cardiol       Date:  2014-02       Impact factor: 5.952

Review 8.  Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis.

Authors:  Philip N Hawkins
Journal:  Curr Opin Nephrol Hypertens       Date:  2002-11       Impact factor: 2.894

Review 9.  Amyloid heart disease.

Authors:  Rodney H Falk; Simon W Dubrey
Journal:  Prog Cardiovasc Dis       Date:  2010 Jan-Feb       Impact factor: 8.194

Review 10.  (11)C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Authors:  Shuo Zhang; Nadja Smailagic; Chris Hyde; Anna H Noel-Storr; Yemisi Takwoingi; Rupert McShane; Juan Feng
Journal:  Cochrane Database Syst Rev       Date:  2014-07-23
View more
  13 in total

Review 1.  Review of cardiovascular imaging in the journal of nuclear cardiology in 2015. Part 1 of 2: Plaque imaging, positron emission tomography, computed tomography, and magnetic resonance.

Authors:  Wael A AlJaroudi; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2015-11-05       Impact factor: 5.952

2.  Role of imaging in cardiac amyloidosis: An ongoing challenge.

Authors:  Ashutosh D Wechalekar
Journal:  J Nucl Cardiol       Date:  2015-11-05       Impact factor: 5.952

Review 3.  Review of Cardiovascular Imaging in the Journal of Nuclear Cardiology in 2016. Part 1 of 2: Positron Emission Tomography, Computed Tomography and Magnetic Resonance.

Authors:  Wael AlJaroudi; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2017-02-13       Impact factor: 5.952

4.  Quantitative molecular imaging of cardiac amyloidosis: The journey has begun.

Authors:  Sharmila Dorbala; Marie Foley Kijewski; Mi-Ae Park
Journal:  J Nucl Cardiol       Date:  2015-07-16       Impact factor: 5.952

5.  Nuclear imaging of cardiac amyloidosis. 'We've only just begun'.

Authors:  Pradeep Bhambhvani; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2016-09-08       Impact factor: 5.952

6.  Positron emission tomography (PET) utilizing Pittsburgh compound B (PIB) for detection of amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR).

Authors:  Björn Pilebro; Sandra Arvidsson; Per Lindqvist; Torbjörn Sundström; Per Westermark; Gunnar Antoni; Ole Suhr; Jens Sörensen
Journal:  J Nucl Cardiol       Date:  2016-09-19       Impact factor: 5.952

Review 7.  Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis.

Authors:  Mathew S Maurer; Sabahat Bokhari; Thibaud Damy; Sharmila Dorbala; Brian M Drachman; Marianna Fontana; Martha Grogan; Arnt V Kristen; Isabelle Lousada; Jose Nativi-Nicolau; Candida Cristina Quarta; Claudio Rapezzi; Frederick L Ruberg; Ronald Witteles; Giampaolo Merlini
Journal:  Circ Heart Fail       Date:  2019-09-04       Impact factor: 8.790

8.  Extracardiac 18F-florbetapir imaging in patients with systemic amyloidosis: more than hearts and minds.

Authors:  T Wagner; J Page; M Burniston; A Skillen; J C Ross; R Manwani; D McCool; P N Hawkins; Ashutosh D Wechalekar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04-12       Impact factor: 9.236

Review 9.  Multimodality Imaging in the Evaluation and Management of Cardiac Amyloidosis.

Authors:  Yiu Ming Khor; Sarah Cuddy; Rodney H Falk; Sharmila Dorbala
Journal:  Semin Nucl Med       Date:  2020-02-09       Impact factor: 4.802

10.  Reproducibility and Repeatability of Assessment of Myocardial Light Chain Amyloidosis Burden Using 18F-Florbetapir PET/CT.

Authors:  Ariana Nodoushani; Mohammed Samir El-Sady; Mi-Ae Park; Gloria L Castilloveitia; Rodney H Falk; Marcelo F Di Carli; Marie Foley Kijewski; Sharmila Dorbala
Journal:  J Nucl Cardiol       Date:  2019-11-22       Impact factor: 3.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.